Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Respiratory Syncytial Virus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02956837 | P2 |
Completed |
Respiratory Syncytial Virus Infections |
2017-08-30 |
|
NCT03191383 | P2 |
Withdrawn |
Respiratory Syncytial Virus Infections |
2017-07-14 |
26% |
NCT02753413 | P2 |
Completed |
Respiratory Syncytial Virus Infections |
2016-06-28 |